Travere Therapeutics Business Summary

Travere Therapeutics, Inc. (TVTX) is a commercial-stage biopharmaceutical company specializing in the development and delivery of therapies for rare kidney and metabolic diseases. The company generates revenue primarily through net product sales of its flagship therapy, FILSPARI (sparsentan), which is the first non-immunosuppressive treatment approved for IgA nephropathy (IgAN), and its cystinuria franchise, Thiola and Thiola EC. Revenue is further bolstered by milestone payments and tiered royalties from strategic collaborations with CSL Vifor and Chugai Pharmaceutical for the international commercialization of sparsentan. Travere’s primary business segments are centered on its rare nephrology franchise, including a pending supplemental New Drug Application (sNDA) for FILSPARI in focal segmental glomerulosclerosis (FSGS) with an April 2026 PDUFA date, and its metabolic pipeline led by pegtibatinase for classical homocystinuria. In the competitive landscape, Travere contends with Calliditas Therapeutics (Tarpeyo) and Novartis (Fabhalta) in the IgAN market, positioning itself as a leader in dual endothelin and angiotensin II receptor antagonism to provide foundational, kidney-protective therapy. The company is led by President and CEO Eric Dube, Ph.D., a former GlaxoSmithKline (GSK) executive and ViiV Healthcare leader with extensive experience in oncology and orphan drug commercialization. The executive team includes CFO Chris Cline, CFA, who previously held leadership roles at Array BioPharma, and Chief Medical Officer Jula Inrig, M.D., a renowned nephrologist and former executive at IQVIA. Travere’s strategic direction is overseen by a board of directors chaired by Gary A. Lyons, a veteran of Neurocrine Biosciences and Genentech. The company maintains a strong institutional investor base, with notable backing from firms such as Aberdeen Group and Lisanti Capital Growth. Since rebranding from Retrophin in 2020, this leadership team has successfully pivoted the organization toward a patient-centric model focused on high-growth rare disease markets and sustainable commercial execution.